Vilon
Also known as: Lys-Glu, KE dipeptide
Vilon (also called Lys-Glu or KE dipeptide) is a khavinson dipeptide in the Short Peptide Bioregulator class. Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue.
For research use only.
Key Facts
- CAS
- 37908-74-6
- Molecular Weight (MW)
- 275.30 g/mol
- Half-life
- Not established in humans
- FDA status
- Not Approved
- Administration Route
- —
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Immune cells (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Feb 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 3
- Listed offers
- 3
- Median price per mg
- $3.00/mg
- Typical $3.00–$3.13/mg
Research summary
Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.
Peptide Library's Vilon profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established for FDA-approved use
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Vilon is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C11H21N3O5 |
|---|---|
| Molecular weight | 275.30 g/mol |
| CAS number | 37908-74-6 |
| Half-life | Not established in humans |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 7010502 |
| FDA UNII | H34V7IM5ML |
| ChEMBL | CHEMBL365790 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but the work remains largely confined to one research group and Russian-language journals, without independent replication or controlled human trials.
Origin
Synthetic Lys-Glu.
Targets
Studies
- Association between Glu504Lys polymorphism of ALDH2 gene and cancer risk: a meta-analysis
- Buried cyclo(Arg-Gly-Tyr(Me)-Lys-Glu) microbubbles
- Graphene oxide nanosheets conjugated PEG-Glu-Lys-Glu copolymer drug delivery system improves drug-loading rates and enables reduction-sensitive drug release and drug tracking
- Hypolipidemic and hypoglycemic effect of peptide Lys-Glu-Trp-NH(2) in rats with associated metabolic disorders
- Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis
Regulatory & research status
Vilon is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Vilon side effects
Side Effects
- Not well characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Vilon: frequently asked questions
What is Vilon?
Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.
How does Vilon work?
Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies.
Is Vilon FDA approved?
No. Vilon is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Vilon?
Reported half-life for Vilon is Not established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Vilon?
Compounds most often compared with Vilon include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Association between Glu504Lys polymorphism of ALDH2 gene and cancer risk: a meta-analysis — PLoS One, 2015External reference
- Buried cyclo(Arg-Gly-Tyr(Me)-Lys-Glu) microbubbles, 2004External reference
- Graphene oxide nanosheets conjugated PEG-Glu-Lys-Glu copolymer drug delivery system improves drug-loading rates and enables reduction-sensitive drug release and drug tracking — J Biomater Sci Polym Ed, 2024External reference
- Hypolipidemic and hypoglycemic effect of peptide Lys-Glu-Trp-NH(2) in rats with associated metabolic disorders — Bull Exp Biol Med, 2014External reference
- Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis — Bull Exp Biol Med, 2014External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Vilon profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Vilon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →